Loading...
*  Deferoxamine - Medical Dictionary / Glossary | Medindia
Deferoxamine' - An iron-chelating agent that removes iron from tumors by inhibiting DNA synthesis and causing cancer cell death ... Medical Word - Deferoxamine. Ans : An iron-chelating agent that removes iron from tumors by inhibiting DNA synthesis and ... Deferoxamine - Glossary. Written & Compiled by Medindia Content Team. Medically Reviewed by The Medindia Medical Review Team on ...
  http://www.medindia.net/glossary/deferoxamine.htm
*  Deferoxamine - DrugBank
Deferoxamine Hydrochloride. G9VYJ96FOJ. 1950-39-6. KCRQZLMAZHZDCL-UHFFFAOYSA-N. Deferoxamine mesylate. V9TKO7EO6K. 138-14-7. ... 100 mg of deferoxamine is capable of binding approximately 8.5 mg of trivalent (ferric) iron. Deferoxamine works in treating ... Pms-Deferoxamine 500 mg/vial. 8.44USD vial. DrugBank does not sell nor buy drugs. Pricing information is supplied for ... Deferoxamine, otherwise known as desferrioxamine or desferal, is a chelating agent used to remove excess iron or aluminum from ...
  https://www.drugbank.ca/drugs/DB00746
*  Deferoxamine - Desferal Summary Report | CureHunter
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, ... Desferal; Desferrioxamine; Deferoxamine B; Deferoxamine Mesilate; Deferoxamine Mesylate; Deferoxamine Methanesulfonate; ... Deferoxamine; Mesylate, Deferoxamine; Mesylate, Desferrioxamine B; Methanesulfonate, Deferoxamine; Butanediamide, N'-(5-((4-((5 ... Deferoxamine (Desferal). Subscribe to New Research on Deferoxamine Natural product isolated from Streptomyces pilosus. It forms ...
  http://www.curehunter.com/public/keywordSummaryD003676-Deferoxamine-Desferal.do
*  Deferoxamine - Desferal Summary | CureHunter Mobile
Also Known As: Desferal; Desferrioxamine; Deferoxamine B; Deferoxamine Mesilate; Deferoxamine Mesylate Show All ,, Networked: ... Deferoxamine (Desferal) Summary Description: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is ... Key Diseases for which Deferoxamine is Relevant. * Iron Overload : 36 outcomes 37 studies in 393 results ...
  http://www.curehunter.com/m/keywordSummaryD003676.do
*  Deferoxamine Lyophilisate For Solution For Injection 2G Drug Medication Dosage Information
... Learn about reported side effects, ... DEFEROXAMINE (dee fer OX a meen) helps to remove excess iron from the body. This may be necessary in patients who have received ...
  https://www.cvs.com/drug/deferoxamine/lyophilisate-for-solution-for-injection/2g
*  Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial - Full Text View - ClinicalTrials.gov
Experimental: Deferoxamine Mesylate Deferoxamine Mesylate (32 mg/kg/day) given by an intravenous infusion for 3 consecutive ... Deferoxamine Mesylate in Intracerebral Hemorrhage Investigators. Safety and tolerability of deferoxamine mesylate in patients ... Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial. The safety and scientific validity of this study is the ... Drug: Deferoxamine Mesylate Placebo Comparator: Normal Saline Normal saline (0.9% sodium chloride) given by intravenous ...
  https://clinicaltrials.gov/ct2/show/NCT02175225
*  Mechanisms underlying the promotion of functional recovery by deferoxamine
Abstract Deferoxamine, a clinically safe drug used for treating iron overload, also repairs spinal cord injury although the ... Mechanisms underlying the promotion of functional recovery by deferoxamine after spinal cord injury in rats. Hao J1, Li B1, ... Deferoxamine, a clinically safe drug used for treating iron overload, also repairs spinal cord injury although the mechanism ... Mechanisms underlying the promotion of functional recovery by deferoxamine Neural Regen Res. 2017 Jun;12(6):959-968. Mechanisms ...
  http://sci.rutgers.edu/forum/showthread.php?260687-Mechanisms-underlying-the-promotion-of-functional-recovery-by-deferoxamine&s=d83c2dafc5927347f4fb3f26f692ecfe&p=1837726
*  Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation
The objective of this research study is to determine the safety and feasibility of chelation therapy with deferoxamine for ... Safety of Deferoxamine Therapy Determined by the Number of Participants With Grade 3 or Higher Toxicities. ... All patients who received chelation therapy were monitored for grade 3 or above toxicity Attributable to Deferoxamine(grades ... A Pilot Study of Deferoxamine Before and During Myeloablative Allogeneic Stem Cell Transplantation for Patients With ...
  http://www.knowcancer.com/cancer-trials/NCT00658411/
*  Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation - Full Text View - ClinicalTrials.gov
Deferoxamine for ,=2 weeks prior to stem cells. Drug: deferoxamine Given intravenously or subcutaneously over 8-12 hours daily ... Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation. The safety and scientific validity of this study is ... Safety of Deferoxamine Therapy Determined by the Number of Participants With Grade 3 or Higher Toxicities. [ Time Frame: ... In this study we are examining the use of deferoxamine starting 2 weeks to 3 months prior to transplantation and continuing ...
  https://clinicaltrials.gov/ct2/show/NCT00658411?term=leukemia+AND+
*  Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major - Tabular View - ClinicalTrials.gov
... deferoxamine), is superior in removing cardiac iron as compared to deferoxamine alone. This trial will provide the first ... Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major. The safety and scientific validity of this ... Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major. Official Title ICMJE A Randomized, Placebo ... This trial tests whether the combination of traditional therapy (deferoxamine) with a newer drug (deferiprone) will prove more ...
  https://clinicaltrials.gov/ct2/show/record/NCT00103753
*  Deferoxamine - Wikipedia
Deferoxamine is a siderophore from the bacteria Streptomyces pilosus. Deferoxamine was approved for medical use in the United ... Deferoxamine is used to treat acute iron poisoning, especially in small children. This agent is also frequently used to treat ... Deferoxamine acts by binding free iron in the bloodstream and enhancing its elimination in the urine. By removing excess iron, ... Deferoxamine is being studied as a treatment for spinal cord injury and intracerebral hemorrhage. It is also used to induce ...
  https://en.wikipedia.org/wiki/Deferoxamine
*  Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients
No known allergy or contraindication to the administration of deferoxamine. - Ability to comply with all study-related ... 20 mg/kg/Day Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients With Iron Overload From Repeated Blood ... 20 mg/kg/Day Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients With Iron Overload From Repeated Blood ...
  http://www.knowcancer.com/cancer-trials/NCT00110617/
*  Enhancement of retinal recovery by conjugated deferoxamine after ischemia-reperfusion. | IOVS | ARVO Journals
Enhancement of retinal recovery by conjugated deferoxamine after ischemia-reperfusion. You will receive an email whenever this ... PURPOSE: Although toxic to the retina in its native form, the iron chelator deferoxamine (DFO) shows no apparent retinal ... P Gehlbach, R L Purple; Enhancement of retinal recovery by conjugated deferoxamine after ischemia-reperfusion.. Invest. ...
  https://iovs.arvojournals.org/article.aspx?articleid=2160878
*  Ascorbate and Deferoxamine Administration after Chlorine Exposure Decrease Mortality and Lung Injury in Mice
... and 0.3 mg of deferoxamine (deferoxamine mesylate; Hospira, Lakeforest, IL) starting at 1 hour after exposure and every 12 ... Ascorbate and deferoxamine treatment decreased BAL lipid peroxidation in Cl2-exposed mice. Mice were exposed to 600 ppm of Cl2 ... Ascorbate and Deferoxamine Treatment Ameliorates Alveolar-Capillary Barrier Damage. As shown in Figure 4, Cl2-exposed mice ... Thus, ascorbate and deferoxamine may need to be administered more frequently, by additional routes (i.e., intravenously), or ...
  http://pubmedcentralcanada.ca/pmcc/articles/PMC3175564/?lang=en-ca
*  Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to...
Deferoxamine. Deferasirox. Siderophores. Iron Chelating Agents. Chelating Agents. Sequestering Agents. Molecular Mechanisms of ... and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO).. This study has been completed. ... of Repeated Doses of 5-30mg/kg/Day ICL670 Relative to Deferoxamine (DFO) in Sickle Cell Disease (SCD) Patients With ...
  https://clinicaltrials.gov/ct2/show/NCT01090323
*  Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias - Full...
Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias. This ... Beta-thalassemia patients unable to be treated with deferoxamine or patients with rare chronic anemias such as Myelodysplastic ... Beta-thalassemia patients with documented non-compliance to deferoxamine, defined as taking less than 50% of prescribed doses ... Beta-thalassemia patients unable to take deferoxamine because of documented side effects or contra-indication, or documented ...
  https://clinicaltrials.gov/ct2/show/NCT00061763?cond=%22Anemia%22&rank=9
*  Deferoxamine mesylate / deferoxamine mesylate NDA 076806 global drug patent coverage, generic alternatives and suppliers
Additional details are available on the DEFEROXAMINE MESYLATE profile page. The generic ingredient in DEFEROXAMINE MESYLATE is ... NDA 076806 describes DEFEROXAMINE MESYLATE, which is a drug marketed by Fresenius Kabi Usa, Gland Pharma Ltd, Hospira, Watson ... deferoxamine mesylate. There are seven drug master file entries for this compound. Four suppliers are listed for this compound ...
  https://www.drugpatentwatch.com/p/NDA/076806
*  Heme oxygenase-1-mediated neuroprotection in subarachnoid hemorrhage via intracerebroventricular deferoxamine | Journal of...
Previous animal studies have explored the therapeutic effects of deferoxamine (DFX) via its iron-chelating properties after SAH ... Iron accumulates in Huntington's disease neurons: protection by deferoxamine. PLoS One. 2013;8(10):e77023.View ArticlePubMed ... Intracerebroventricular deferoxamine injection dose-tolerance in wild-type mice. In order to determine the dose of DFX to be ... Intraperitoneal injection of deferoxamine. Starting on SAH POD1, 24-h after the induced SAH, the mice were given systemic ...
  https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-016-0709-1
*  Deferoxamine mesylate / deferoxamine mesylate FDA New drug application 076019 global drug patent coverage, generic alternatives...
DEFEROXAMINE MESYLATE. deferoxamine mesylate. INJECTABLE;INJECTION. 076019. ANDA. Hospira, Inc.. 0409-2336. 0409-2336-10. 4 ... DEFEROXAMINE MESYLATE. deferoxamine mesylate. INJECTABLE;INJECTION. 076019. ANDA. Hospira, Inc.. 0409-2336. 0409-2336-13. 10 ... Additional details are available on the DEFEROXAMINE MESYLATE profile page. The generic ingredient in DEFEROXAMINE MESYLATE is ... NDA 076019 describes DEFEROXAMINE MESYLATE, which is a drug marketed by Fresenius Kabi Usa, Gland Pharma Ltd, Hospira, Watson ...
  https://www.drugpatentwatch.com/p/NDA/076019
*  Abstract 336: Cardiac Function Improvement in Infarcted Rats Treated with an Association of N-acetylcysteine and Deferoxamine |...
Our aim was to test the association of NAC and an iron chelator (deferoxamine - DFX) on cardiac remodeling in a rodent model of ... Abstract 336: Cardiac Function Improvement in Infarcted Rats Treated with an Association of N-acetylcysteine and Deferoxamine. ... Abstract 336: Cardiac Function Improvement in Infarcted Rats Treated with an Association of N-acetylcysteine and Deferoxamine ... Abstract 336: Cardiac Function Improvement in Infarcted Rats Treated with an Association of N-acetylcysteine and Deferoxamine ...
  http://circres.ahajournals.org/content/115/Suppl_1/A336
*  Distortion-product otoacoustic emission: early detection in deferoxamine induced ototoxicity - UnissResearch
Deferoxamine therapy in lifelong transfusion-dependent anaemias, as beta-thalassemia major, is associated with an increased ... Deferoxamine, ototoxicity, pure-tone audiometry, distortion-product otoacoustic emissions. Subjects:. Area 06 - Scienze mediche ... early detection in deferoxamine induced ototoxicity.. Auris Nasus Larynx, Vol. 35 (2), p. 198-202. ISSN 0385-8146. Article. ...
  http://eprints.uniss.it/1976/
*  "Deferoxamine effects on Plasmodium falciparum gene expression" by Ann M. Moormann, Paul A. Hossler et al.
Moormann, Ann M.; Hossler, Paul A.; and Meshnick, Steven R., "Deferoxamine effects on Plasmodium falciparum gene expression" ( ... Animals; Antimalarials; Deferoxamine; Gene Expression; Iron; Iron Chelating Agents; Mitochondria; Plasmodium falciparum ...
  https://escholarship.umassmed.edu/qhs_pp/381/
*  Deferoxamine retinopathy: spectral domain-optical coherence tomography findings | BMC Ophthalmology | Full Text
Spectral domain optical coherence tomographyDeferoxamineRetinopathy. Background. Deferoxamine is an iron-chelating agent used ... Deferoxamine is a widely used chelating agent in treating transfusional hemochromatosis [1, 5]. Visual symptoms included ... Deferoxamine retinopathy primarily targets the RPE-Bruch membrane-photoreceptor complex, extending from the peri-fovea to the ... The pathophysiology of deferoxamine-related retinopathy has been investigated for several years. Rahi et al. first reported ...
  https://bmcophthalmol.biomedcentral.com/articles/10.1186/1471-2415-14-88